| Year |
Citation |
Score |
| 2024 |
Wissing M, Brimo F, McKercher G, Scarlata E, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Chevalier S, Aprikian A. Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada. Human Pathology. 146: 66-74. PMID 38608782 DOI: 10.1016/j.humpath.2024.04.002 |
0.493 |
|
| 2023 |
Derderian S, Benidir T, Scarlata E, Altaylouni T, Hamel L, Zouanat FZ, Brimo F, Aprikian A, Chevalier S. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression. The Journal of Pathology. Clinical Research. PMID 37073437 DOI: 10.1002/cjp2.319 |
0.749 |
|
| 2023 |
Ebrahimizadeh W, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Patel PG, Jamaspishvili T, Hamel L, Aprikian AG, Lee AY, Berman DM, Bartlett JMS, Chevalier S, Lapointe J. A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. British Journal of Cancer. PMID 37037938 DOI: 10.1038/s41416-023-02236-8 |
0.71 |
|
| 2022 |
Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 36373402 DOI: 10.1097/JU.0000000000003049 |
0.526 |
|
| 2022 |
Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C. Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer. British Journal of Cancer. PMID 36347965 DOI: 10.1038/s41416-022-02040-w |
0.432 |
|
| 2022 |
Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, ... ... Chevalier S, et al. UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. Cancer Letters. 215994. PMID 36343786 DOI: 10.1016/j.canlet.2022.215994 |
0.519 |
|
| 2022 |
Derderian S, Vesval Q, Wissing MD, Hamel L, Côté N, Vanhuyse M, Ferrario C, Bladou F, Aprikian A, Chevalier S. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clinical and Translational Science. PMID 36172886 DOI: 10.1111/cts.13372 |
0.662 |
|
| 2022 |
Bramhecha YM, Guérard KP, Audet-Walsh É, Rouzbeh S, Kassem O, Pernet E, Scarlata E, Hamel L, Brimo F, Divangahi M, Aprikian AG, Chevalier S, Giguère V, Lapointe J. Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. Oncogene. PMID 35411033 DOI: 10.1038/s41388-022-02276-z |
0.717 |
|
| 2021 |
Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C, Lévesque E. Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. British Journal of Cancer. PMID 33828256 DOI: 10.1038/s41416-021-01376-z |
0.52 |
|
| 2020 |
Ebrahimizadeh W, Guérard KP, Rouzbeh S, Bramhecha YM, Scarlata E, Brimo F, Patel PG, Jamaspishvili T, Aprikian AG, Berman D, Bartlett J, Chevalier S, Lapointe J. Design and development of a fully synthetic MLPA-based probe mix for detection of copy number alterations in prostate cancer formalin-fixed, paraffin-embedded tissue samples. The Journal of Molecular Diagnostics : Jmd. PMID 32763409 DOI: 10.1016/J.Jmoldx.2020.07.003 |
0.427 |
|
| 2019 |
Patel PG, Wessel T, Kawashima A, Okello JBA, Jamaspishvili T, Guérard KP, Lee L, Lee AY, How NE, Dion D, Scarlata E, Jackson CL, Boursalie S, Sack T, Dunn R, ... ... Chevalier S, et al. A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer. The Prostate. PMID 31433512 DOI: 10.1002/Pros.23895 |
0.52 |
|
| 2019 |
Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, Cury FL, Tanguay S, Aprikian AG, Kassouf W, Chevalier S. Improving ultrasound-based prostate volume estimation. Bmc Urology. 19: 68. PMID 31340802 DOI: 10.1186/S12894-019-0492-2 |
0.715 |
|
| 2019 |
Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, et al. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. Plos Medicine. 16: e1002847. PMID 31265453 DOI: 10.1371/Journal.Pmed.1002847 |
0.583 |
|
| 2019 |
Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A. Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada. Psycho-Oncology. PMID 30762265 DOI: 10.1002/Pon.5031 |
0.511 |
|
| 2019 |
Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C. A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30733309 DOI: 10.1158/1055-9965.Epi-18-1002 |
0.595 |
|
| 2018 |
Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, et al. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. Bmc Urology. 18: 78. PMID 30200929 DOI: 10.1186/S12894-018-0392-X |
0.577 |
|
| 2018 |
Bramhecha YM, Rouzbeh S, Guérard KP, Scarlata E, Brimo F, Chevalier S, Hamel L, Aprikian AG, Lapointe J. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30140035 DOI: 10.1038/S41379-018-0107-6 |
0.72 |
|
| 2018 |
Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, Aprikian A. The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. World Journal of Urology. PMID 30136199 DOI: 10.1007/S00345-018-2457-6 |
0.5 |
|
| 2018 |
Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, et al. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. Bju International. PMID 30113732 DOI: 10.1111/Bju.14512 |
0.567 |
|
| 2018 |
Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. Bmc Health Services Research. 18: 430. PMID 29884180 DOI: 10.1186/S12913-018-3273-9 |
0.478 |
|
| 2018 |
Saad F, Fitch M, Pang K, Ouellet V, Loiselle C, Chevalier S, Drachenberg D, Finelli A, Sutcliffe S, So AI, Tanguay S, Mes-Masson A. Perspectives of prostate cancer patients about active surveillance. Journal of Clinical Oncology. 36: 82-82. DOI: 10.1200/Jco.2018.36.6_Suppl.82 |
0.427 |
|
| 2018 |
Saad F, Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg D, Finelli A, Lattouf J, So A, Sutcliffe S, Tanguay S, Mes-Masson A. Perspectives of health care professionals on active surveillance for the management of prostate cancer. Journal of Clinical Oncology. 36: 81-81. DOI: 10.1200/Jco.2018.36.6_Suppl.81 |
0.468 |
|
| 2018 |
Saad F, Ouellet V, Grosset A, Caron C, Barres V, Latour M, Trudel D, Aprikian AG, Bergeron A, Brimo F, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, et al. Nuclear factor-kappa B p65 evaluation on the Canadian Prostate Cancer Biomarker Network (CPCBN) TMA-series for biomarker validation. Journal of Clinical Oncology. 36: 80-80. DOI: 10.1200/Jco.2018.36.6_Suppl.80 |
0.431 |
|
| 2018 |
Berman DM, Lesurf R, Lee AY, Patel P, Jamaspishvili T, Ebrahimizadeh W, Okello J, Rouzbeh S, Boufaied N, Lee LA, Chevalier S, Brimo F, Venkateswaran V, Park PC, Buttyan R, et al. Personalized risk stratification for patients with early prostate cancer (PRONTO): A Canadian team biomarker project. Journal of Clinical Oncology. 36: 109-109. DOI: 10.1200/Jco.2018.36.6_Suppl.109 |
0.5 |
|
| 2017 |
Fitch M, Pang K, Ouellet V, Loiselle C, Alibhai S, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Sutcliffe S, So A, Tanguay S, Saad F, Mes-Masson AM. Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources. Bmc Urology. 17: 98. PMID 29078772 DOI: 10.1186/S12894-017-0290-7 |
0.578 |
|
| 2017 |
Bramhecha YM, Guérard KL, Rouzbeh S, Scarlata EM, Brimo F, Chevalier SMA, Hamel L, Dragomir A, Aprikian A, Lapointe J. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome After Surgical Intervention. Molecular Cancer Research : McR. PMID 28993510 DOI: 10.1158/1541-7786.Mcr-17-0270 |
0.675 |
|
| 2017 |
Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes & Development. PMID 28724614 DOI: 10.1101/Gad.299958.117 |
0.718 |
|
| 2017 |
Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer. PMID 28152543 DOI: 10.1038/Bjc.2017.15 |
0.761 |
|
| 2017 |
Altaylouni T, Zouanat F, Scarlata E, Benidir T, Hamel L, Brimo F, Bégin L, Aprikian A, Chevalier S. PD65-12 THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223 Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2962 |
0.733 |
|
| 2016 |
Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S. A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks. Biopreservation and Biobanking. PMID 27327090 DOI: 10.1089/Bio.2015.0113 |
0.32 |
|
| 2016 |
Sanyal C, Aprikian AG, Cury FL, Chevalier S, Dragomir A. Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. Cancer. 122: 1085-96. PMID 26828716 DOI: 10.1002/Cncr.29892 |
0.443 |
|
| 2016 |
Mansure JJ, Solanki S, Alamjed W, Nassim R, Cury F, Chevalier S, Kassouf W. Abstract 1654: p21 WAF1/Cip1 -mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis Cancer Research. 76: 1654-1654. DOI: 10.1158/1538-7445.Am2016-1654 |
0.389 |
|
| 2015 |
Chevalier S, Moffett S, Turcotte E, Luz M, Chauvette L, Derbekyan V, Scarlata E, Zouanat F, Aprikian AG, Anidjar M. The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases. Ejnmmi Research. 5: 77. PMID 26714499 DOI: 10.1186/S13550-015-0155-6 |
0.583 |
|
| 2015 |
Cury FL, Bhindi B, Rocha J, Scarlata E, El Jurdi K, Ladouceur M, Beauregard S, Vijh AK, Taguchi Y, Chevalier S. Electrochemical red-ox therapy of prostate cancer in nude mice. Bioelectrochemistry (Amsterdam, Netherlands). 104: 1-9. PMID 25578541 DOI: 10.1016/J.Bioelechem.2014.12.004 |
0.475 |
|
| 2014 |
Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A. Clinical management and burden of prostate cancer: a Markov Monte Carlo model. Plos One. 9: e113432. PMID 25474006 DOI: 10.1371/Journal.Pone.0113432 |
0.485 |
|
| 2014 |
Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A. Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. Human Pathology. 45: 2006-13. PMID 25152453 DOI: 10.1016/J.Humpath.2014.06.014 |
0.492 |
|
| 2014 |
Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizafoun N, Dragomir A, Tanguay S, Kassouf W, Aprikian A, Brimo F. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. Human Pathology. 45: 488-97. PMID 24406017 DOI: 10.1016/J.Humpath.2013.10.012 |
0.622 |
|
| 2013 |
Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S. Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank. Biopreservation and Biobanking. 11: 285-90. PMID 24194978 DOI: 10.1089/Bio.2013.0025 |
0.746 |
|
| 2013 |
Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Molecular and Cellular Endocrinology. 381: 140-9. PMID 23906537 DOI: 10.1016/J.Mce.2013.07.017 |
0.761 |
|
| 2013 |
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W. Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment. Plos One. 8: e65257. PMID 23799002 DOI: 10.1371/Journal.Pone.0065257 |
0.365 |
|
| 2013 |
Chevalier S, Cury FL, Scarlata E, El-Zayat E, Hamel L, Rocha J, Zouanat FZ, Moussa S, Scherz A, Elhilali M, Anidjar M. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model. The Journal of Urology. 190: 1946-53. PMID 23680311 DOI: 10.1016/J.Juro.2013.05.014 |
0.741 |
|
| 2013 |
Mansure JJ, Nassim R, Chevalier S, Szymanski K, Rocha J, Aldousari S, Kassouf W. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. Plos One. 8: e55997. PMID 23409107 DOI: 10.1371/Journal.Pone.0055997 |
0.316 |
|
| 2013 |
Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A. Direct cost for initial management of prostate cancer: A systematic review Current Oncology. 20. DOI: 10.3747/Co.20.1630 |
0.361 |
|
| 2012 |
Choucair KA, Guérard KP, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J. The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology. 5: 453-60. PMID 23401739 DOI: 10.1593/Tlo.12286 |
0.549 |
|
| 2012 |
Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. Bmc Cancer. 12: 543. PMID 23171135 DOI: 10.1186/1471-2407-12-543 |
0.591 |
|
| 2012 |
Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A. Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. Cell and Tissue Banking. 13: 631-8. PMID 22200970 DOI: 10.1007/S10561-011-9284-Y |
0.523 |
|
| 2012 |
Anidjar M, Scarlata E, Cury FL, Rocha J, Hamel L, Luz M, Chevalier S. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. The Prostate. 72: 752-61. PMID 21882212 DOI: 10.1002/Pros.21479 |
0.762 |
|
| 2012 |
Choucair K, Brimo F, Cunha IW, Aprikian A, Gleave M, Lapointe J, Guerard K, Ejdelman J, Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA. Abstract C25: The 16p13.3 genomic gain in prostate cancer: A role for PDK1 in disease progression Cancer Research. 72: C25-C25. DOI: 10.1158/1538-7445.Prca2012-C25 |
0.505 |
|
| 2012 |
Nassim R, Mansure J, Chevalier S, Cury F, Parker W, Davis S, Cury J, Kassouf W. Abstract 1452: mTOR inhibition radiosensitizes bladder cancer tumor cellsin vitroandin vivo: A novel strategy for treatment Cancer Research. 72: 1452-1452. DOI: 10.1158/1538-7445.Am2012-1452 |
0.394 |
|
| 2011 |
Chan SW, Nguyen PN, Ayele D, Chevalier S, Aprikian A, Chen JZ. Mitochondrial DNA damage is sensitive to exogenous H(2)O(2) but independent of cellular ROS production in prostate cancer cells. Mutation Research. 716: 40-50. PMID 21843533 DOI: 10.1016/J.Mrfmmm.2011.07.019 |
0.467 |
|
| 2011 |
Chevalier S, Anidjar M, Scarlata E, Hamel L, Scherz A, Ficheux H, Borenstein N, Fiette L, Elhilali M. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate. The Journal of Urology. 186: 302-9. PMID 21600602 DOI: 10.1016/J.Juro.2011.03.039 |
0.707 |
|
| 2011 |
Lu Y, Bedard N, Chevalier S, Wing SS. Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells. Plos One. 6: e15936. PMID 21264218 DOI: 10.1371/Journal.Pone.0015936 |
0.487 |
|
| 2010 |
Mansure JJ, Szymanski K, Nassim R, Rocha J, Aldousari S, Chevalier S, Kassouf W. Abstract 5405: PPARγ-agonist can render bladder tumor sensitive to EGFR inhibition Cancer Research. 70: 5405-5405. DOI: 10.1158/1538-7445.Am10-5405 |
0.375 |
|
| 2010 |
Rocha J, Zouanat F, Zoubeidi A, Hamel L, Aprikian A, Chevalier S. 546 ANDROGEN RECEPTOR ACTIVATION BY THE FER KINASE IN PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.766 |
0.807 |
|
| 2010 |
Luz M, Dal Pra A, Chevalier S, Aprikian A, Scarlata E, Hamel L, Cury F. Prostate Volume Assessment Prior Brachytherapy Implant - How Accurate is Trans-rectal Ultrasound? International Journal of Radiation Oncology*Biology*Physics. 78: S374-S375. DOI: 10.1016/J.Ijrobp.2010.07.883 |
0.712 |
|
| 2009 |
Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biology & Therapy. 8: 2339-47. PMID 20061787 DOI: 10.4161/Cbt.8.24.9987 |
0.379 |
|
| 2009 |
Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, Rocchi P, Giusiano S, Elzayat EA, Corcos J. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. The Prostate. 69: 1143-50. PMID 19399787 DOI: 10.1002/Pros.20958 |
0.634 |
|
| 2009 |
Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Molecular Cancer Research : McR. 7: 142-55. PMID 19147545 DOI: 10.1158/1541-7786.Mcr-08-0117 |
0.826 |
|
| 2007 |
Wang JC, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2354-61. PMID 17406028 DOI: 10.1158/1078-0432.Ccr-06-1692 |
0.379 |
|
| 2005 |
Lacoste J, Aprikian AG, Chevalier S. Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility. Molecular and Cellular Endocrinology. 235: 51-61. PMID 15866427 DOI: 10.1016/J.Mce.2004.06.014 |
0.589 |
|
| 2005 |
Doré M, Chevalier S, Sirois J. Estrogen-dependent induction of cyclooxygenase-2 in the canine prostate in vivo Veterinary Pathology. 42: 100-103. PMID 15657282 DOI: 10.1354/vp.42-1-100 |
0.556 |
|
| 2004 |
Kassouf W, Ismail HR, Aprikian AG, Chevalier S. Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer and Prostatic Diseases. 7: 105-10. PMID 15175661 DOI: 10.1038/Sj.Pcan.4500716 |
0.642 |
|
| 2004 |
Ismail AH, Altaweel W, Chevalier S, Kassouf W, Aprikian AG. Expression of vascular endothelial growth factor-A in human lymph node metastases of prostate cancer. The Canadian Journal of Urology. 11: 2146-50. PMID 15003156 |
0.46 |
|
| 2002 |
Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Bégin LR, Aprikian AG. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Molecular and Cellular Endocrinology. 189: 169-79. PMID 12039075 DOI: 10.1016/S0303-7207(01)00728-6 |
0.813 |
|
| 2002 |
Ismail A HR, Landry F, Aprikian AG, Chevalier S. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. The Prostate. 51: 117-25. PMID 11948966 DOI: 10.1002/pros.10066 |
0.532 |
|
| 2002 |
Omar EA, Behlouli H, Chevalier S, Aprikian AG. Relationship of p21(WAF-I) protein expression with prognosis in advanced prostate cancer treated by androgen ablation. The Prostate. 49: 191-9. PMID 11746264 DOI: 10.1002/Pros.1134 |
0.479 |
|
| 2000 |
Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. European Journal of Biochemistry / Febs. 267: 5550-60. PMID 10951214 DOI: 10.1046/j.1432-1327.2000.01621.x |
0.544 |
|
| 2000 |
Allard P, Beaulieu P, Aprikian A, Chevalier S. Bombesin modulates the association of Src with a nuclear 110-kd protein expressed in dividing prostate cells. Journal of Andrology. 21: 367-75. PMID 10819444 DOI: 10.1002/J.1939-4640.2000.Tb03391.X |
0.798 |
|
| 2000 |
Allard P, Zoubeidi A, Nguyen LT, Tessier S, Tanguay S, Chevrette M, Aprikian A, Chevalier S. Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Molecular and Cellular Endocrinology. 159: 63-77. PMID 10687853 DOI: 10.1016/S0303-7207(99)00205-1 |
0.831 |
|
| 1999 |
Guy L, Defoy I, Al-Othman K, Aprikian AG, Chevalier S. Vascular Endothelial Growth Factor (Vegf) In Human Prostate Cancer: More Than Angiogenesis The Journal of Urology. 53. DOI: 10.1097/00005392-199904010-00213 |
0.789 |
|
| 1998 |
Guy L, Bégin LR, Al-Othman K, Chevalier S, Aprikian AG. Neuroendocrine cells of the verumontanum: a comparative immunohistochemical study. British Journal of Urology. 82: 738-43. PMID 9839592 DOI: 10.1046/j.1464-410X.1998.00812.x |
0.523 |
|
| 1998 |
Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer The Prostate. 36: 52-61. DOI: 10.1002/(SICI)1097-0045(1998)8+<52::AID-PROS9>3.0.CO;2-I |
0.402 |
|
| 1997 |
Aprikian AG, Tremblay L, Han K, Chevalier S. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. International Journal of Cancer. 72: 498-504. PMID 9247295 DOI: 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.0.CO;2-8 |
0.323 |
|
| 1997 |
Han K, Viallet J, Chevalier S, Zheng W, Bazinet M, Aprikian AG. Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. The Prostate. 31: 53-60. PMID 9108887 DOI: 10.1002/(Sici)1097-0045(19970401)31:1<53::Aid-Pros9>3.0.Co;2-J |
0.455 |
|
| 1997 |
Allard P, Atfi A, Landry F, Chapdelaine A, Chevalier S. Estradiol activates p60src, p53/56lyn and renatured p50/55 protein tyrosine kinases in the dog prostate. Molecular and Cellular Endocrinology. 126: 25-34. PMID 9027360 DOI: 10.1016/S0303-7207(96)03966-4 |
0.798 |
|
| 1996 |
Nguyen LT, Beauregard G, Tessier S, Allard P, Atfi A, Durocher Y, Chapdelaine A, Potier M, Chevalier S. Radiation inactivation and in situ renaturation of protein tyrosine kinases reveal a major 50-kDa enzyme as part of a membrane complex present in dividing but not in resting prostatic epithelial cells. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 74: 75-85. PMID 9035692 |
0.699 |
|
| 1996 |
Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. International Journal of Cancer. 68: 164-71. PMID 8900422 DOI: 10.1002/(Sici)1097-0215(19961009)68:2<169::Aid-Ijc4>3.0.Co;2-W |
0.543 |
|
| 1996 |
Tremblay L, Hauck W, Nguyen LT, Allard P, Landry F, Chapdelaine A, Chevalier S. Regulation and activation of focal adhesion kinase and paxillin during the adhesion, proliferation, and differentiation of prostatic epithelial cells in vitro and in vivo. Molecular Endocrinology (Baltimore, Md.). 10: 1010-20. PMID 8843417 DOI: 10.1210/Mend.10.8.8843417 |
0.787 |
|
| 1996 |
Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. Journal of Molecular Endocrinology. 16: 297-306. PMID 8782088 DOI: 10.1677/jme.0.0160297 |
0.426 |
|
| 1995 |
Boissonneault M, Chapdelaine A, Chevalier S. The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases. Molecular and Cellular Biochemistry. 153: 139-44. PMID 8927029 DOI: 10.1007/Bf01075929 |
0.631 |
|
| 1995 |
Atfi A, Lepage K, Allard P, Chapdelaine A, Chevalier S. Activation of a serine/threonine kinase signaling pathway by transforming growth factor type beta. Proceedings of the National Academy of Sciences of the United States of America. 92: 12110-4. PMID 8618854 |
0.628 |
|
| 1991 |
Chevalier S, McKercher G, Chapdelaine A. Serum and prostatic growth-promoting factors for steroid-independent epithelial cells of adult dog prostate. The Prostate. 19: 207-20. PMID 1946040 DOI: 10.1002/pros.2990190303 |
0.494 |
|
| 1991 |
Bourassa C, Nguyen LT, Durocher Y, Roberts KD, Chevalier S. Prostatic epithelial cells in culture: Phosphorylation of protein tyrosyl residues and tyrosine protein kinase activity Journal of Cellular Biochemistry. 46: 291-301. PMID 1721913 DOI: 10.1002/jcb.240460404 |
0.367 |
|
| 1991 |
Bourassa C, Nguyen LT, Roberts KD, Chevalier S. Characterization of protein-tyrosine kinase activity in the canine prostate Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 69: 146-153. PMID 1709564 DOI: 10.1139/o91-022 |
0.335 |
|
| 1991 |
Chevalier S, Chapdelaine A. Involvement of vitronectin and of a natural extracellular matrix in prostatic cell to cell contact and interaction with the substratum in culture. The Prostate. 18: 9-24. PMID 1702890 DOI: 10.1002/pros.2990180103 |
0.419 |
|
| 1990 |
Chevalier S, Turcotte G, McKercher G, Boulanger P, Chapdelaine A. Steroid metabolism and binding in relation to prostatic cell growth and differentiation in vitro. Annals of the New York Academy of Sciences. 595: 173-83. PMID 2375603 DOI: 10.1111/j.1749-6632.1990.tb34291.x |
0.419 |
|
| 1990 |
Durocher Y, Chevalier S. Protein tyrosine kinases in human breast cancer: Kinetic properties and evidence for the presence of two forms of native enzyme Breast Cancer Research and Treatment. 17: 99-107. PMID 2096998 DOI: 10.1007/Bf01806290 |
0.306 |
|
| 1989 |
Tessier S, Chapdelaine A, Chevalier S. Effect of vanadate on protein phosphorylation and on acid phosphatase activity in the canine prostate. Molecular and Cellular Endocrinology. 64: 87-94. PMID 2759342 DOI: 10.1016/0303-7207(89)90068-3 |
0.441 |
|
| 1989 |
Tessier S, Chapdelaine A, Chevalier S. Alkali-resistant protein phosphorylation and tyrosine kinase activity of epithelial cell types from normal and metaplastic canine prostates. Molecular and Cellular Endocrinology. 66: 59-70. PMID 2583363 DOI: 10.1016/0303-7207(89)90049-X |
0.499 |
|
| 1988 |
Bourassa C, Chapdelaine A, Roberts KD, Chevalier S. Enhancement of the detection of alkali-resistant phosphoproteins in polyacrylamide gels. Analytical Biochemistry. 169: 356-62. PMID 3382008 DOI: 10.1016/0003-2697(88)90295-3 |
0.333 |
|
| 1988 |
Turcotte G, Chapdelaine A, Roberts KD, Chevalier S. Androgen binding as evidenced by a whole cell assay system using cultured canine prostatic epithelial cells. Journal of Steroid Biochemistry. 29: 69-76. PMID 3258047 DOI: 10.1016/0022-4731(88)90378-0 |
0.365 |
|
| 1988 |
Chevalier S, Landry D, Chapdelaine A. Phosphotyrosine phosphatase activity of human and canine acid phosphatases of prostatic origin. The Prostate. 12: 209-19. PMID 2836832 DOI: 10.1002/pros.2990120304 |
0.373 |
|
| 1988 |
Chevalier S, Chapdelaine A. Requirements for attachment and subsequent growth of canine prostatic epithelial cells in culture. The Prostate. 12: 231-41. PMID 2453861 DOI: 10.1002/pros.2990120306 |
0.44 |
|
| 1986 |
McKercher G, Chevalier S, Roberts KD, Bleau G, Chapdelaine A. Dihydrotestosterone and 3 alpha-androstanediol dynamics in the normal, involuted, and hyperplastic canine prostate. Steroids. 48: 55-72. PMID 2444022 DOI: 10.1016/0039-128X(86)90041-3 |
0.337 |
|
| 1985 |
Lamarre D, Chevalier S, McKercher G, Bleau G, Roberts KD, Chapdelaine A. Quantification of cytosolic steroid receptors in secretory and non-secretory epithelial cells of the canine prostate. Journal of Steroid Biochemistry. 22: 1-7. PMID 3871877 DOI: 10.1016/0022-4731(85)90134-7 |
0.352 |
|
| 1985 |
Chevalier S, Bleau G, Roberts K, Chapdelaine A. Nonsteroidal Serum Factors Involved in the Regulation of the Proliferation of Canine Prostatic Epithelial Cells in Culture Journal of Urology. 133: 552-552. DOI: 10.1016/S0022-5347(17)49080-X |
0.46 |
|
| 1983 |
Dionne FT, Chevalier S, Bleau G, Roberts KD, Chapdelaine A. Induction of acid phosphatase synthesis in canine prostatic epithelial cells in vitro. Molecular and Cellular Endocrinology. 33: 113-26. PMID 6357896 DOI: 10.1016/0303-7207(83)90060-6 |
0.318 |
|
| 1980 |
Chevalier S, Bleau G, Roberts KD, Chapdelaine A. Characterization of canine prostatic cells from normal and hyperplastic glands. Molecular and Cellular Endocrinology. 20: 59-70. PMID 6160068 DOI: 10.1016/0303-7207(80)90094-5 |
0.426 |
|
| 1975 |
Chevalier S, Verly WG. Identification of the inhibitor of labelled thymidine incorporation into HeLa cell DNA present in endometrial extract. European Journal of Cancer. 11: 657-67. PMID 1220980 |
0.491 |
|
| Show low-probability matches. |
